ImageneBio, Inc.IMAEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of precision oncology therapies and targeted radiopharmaceuticals for hard-to-treat cancers. It primarily serves the North American healthcare market, with a core focus on advancing personalized treatment options matched to patients’ unique genomic profiles.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 8.48% | 4.1M | — | 2024-11-14 |
| Gilead Sciences, Inc. | 6.70% | 2.9M | — | 2023-10-19 |
| OrbiMed Advisors LLC | 5.20% | 2.2M | ▼ -0.30pp | 2023-09-21 |
| Biotechnology Value Fund, L.P. | 5.10% | 2.5M | — | 2024-02-14 |
| Omega Fund VI, L.P. | 4.70% | 2.2M | — | 2024-02-14 |
| BRISTOL-MYERS SQUIBB COMPANY | 4.40% | 2.1M | — | 2024-11-13 |
| FMR LLC | 2.77% | 1.2M | ▼ -6.77pp | 2024-03-11 |
| Citadel Advisors LLC | 0.30% | 48.3M | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-16 | Kristin Yarema | Chief Executive Officer | Grant | 85.4K | $0.00 | $0 |
1–1 of 1